Drugs / Hepatitis A

Trials 5 · a red edge is where a trial was stopped

20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 44 trials
Phase 4 NCT06038617 Oct 2023 → Apr 2025 Duke University Completed No outcome recorded
Phase 4 NCT02868970 Feb 2017 → Jul 2021 Canadian Immunization Research Network Completed No outcome recorded
Phase 4 NCT00329251 Apr 2003 → Mar 2006 HIV infectious disease Hospital Clinic of Barcelona Completed No outcome recorded
Phase 4 NCT00131820 Dec 2001 → Jan 2007 paratyphoid fever, typhoid fever International Vaccine Institute Completed No outcome recorded
Phase not applicable1 trial
NCT03180359 Jan 2016 → Oct 2019 disease related to transplantation Hospices Civils de Lyon Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT00483574 Background May 2007 → Jan 2009 chickenpox, measles, meningococcal meningitis, mumps infectious disease +1 Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase not applicable1 trial
NCT06313762 Background Jan 2022 → Jan 2024 Jordi Gol Institute for Primary Care Research Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Hepatitis A “Pneumococcal, DTaP, Haemophilus Influenzae Type B, MMR, Varicella, MMRV, Hepatitis A, Inactivated Poliovirus, Hepatitis B, Rotavirus, Influenza vaccines” NCT06038617
6

“* Hepatitis ANCT03180359

NCT02868970

NCT00131820

NCT06313762

NCT00483574

NCT00329251

Modality Vaccine “Routine paediatric vaccine - Hepatitis A” NCT00483574
Route Intramuscular “0.5 mL, Intramuscular at age 12 months” NCT00483574